AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Hold” from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has received an average rating of “Hold” from the six brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $34.67.

Several analysts have recently weighed in on ANAB shares. Wedbush restated a “neutral” rating on shares of AnaptysBio in a report on Monday, March 15th. JPMorgan Chase & Co. cut AnaptysBio from an “overweight” rating to an “underweight” rating in a report on Monday, March 8th. Zacks Investment Research upgraded AnaptysBio from a “sell” rating to a “hold” rating in a report on Thursday, March 11th. Truist Securities upgraded AnaptysBio from a “hold” rating to a “buy” rating and upped their target price for the company from $27.00 to $34.00 in a report on Monday, March 22nd. Finally, Truist upgraded AnaptysBio from a “hold” rating to a “buy” rating and upped their target price for the company from $27.00 to $34.00 in a report on Tuesday, March 16th.

In other AnaptysBio news, major shareholder Ecor1 Capital, Llc purchased 29,500 shares of the company’s stock in a transaction on Tuesday, February 23rd. The shares were purchased at an average cost of $25.48 per share, with a total value of $751,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders acquired 2,920,800 shares of company stock worth $56,121,930. Insiders own 13.00% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. EcoR1 Capital LLC lifted its stake in AnaptysBio by 121.9% in the first quarter. EcoR1 Capital LLC now owns 7,151,624 shares of the biotechnology company’s stock valued at $154,117,000 after buying an additional 3,928,300 shares during the period. BlackRock Inc. raised its position in shares of AnaptysBio by 9.9% during the first quarter. BlackRock Inc. now owns 2,096,138 shares of the biotechnology company’s stock worth $45,171,000 after purchasing an additional 188,304 shares during the period. Dimensional Fund Advisors LP raised its position in shares of AnaptysBio by 11.8% during the first quarter. Dimensional Fund Advisors LP now owns 655,712 shares of the biotechnology company’s stock worth $14,130,000 after purchasing an additional 69,160 shares during the period. Rock Springs Capital Management LP raised its position in shares of AnaptysBio by 73.0% during the first quarter. Rock Springs Capital Management LP now owns 535,232 shares of the biotechnology company’s stock worth $11,534,000 after purchasing an additional 225,819 shares during the period. Finally, Palo Alto Investors LP raised its position in shares of AnaptysBio by 4.9% during the first quarter. Palo Alto Investors LP now owns 436,592 shares of the biotechnology company’s stock worth $9,409,000 after purchasing an additional 20,300 shares during the period.

AnaptysBio stock traded down $0.18 during midday trading on Monday, reaching $25.92. The company’s stock had a trading volume of 253,035 shares, compared to its average volume of 467,781. AnaptysBio has a 52 week low of $13.92 and a 52 week high of $35.85. The business has a 50-day moving average price of $23.06 and a 200-day moving average price of $25.07. The stock has a market cap of $709.40 million, a PE ratio of -9.56 and a beta of 0.15.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, May 3rd. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.03. Research analysts anticipate that AnaptysBio will post 0.04 EPS for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Featured Story: Dividend

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.